Progyny (PGNY) Competitors $19.49 -0.01 (-0.05%) Closing price 04:00 PM EasternExtended Trading$19.35 -0.14 (-0.72%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PGNY vs. RDNT, BTSG, SHC, OPCH, WGS, PRVA, HTFL, VCYT, CON, and SGRYShould you be buying Progyny stock or one of its competitors? The main competitors of Progyny include RadNet (RDNT), BrightSpring Health Services (BTSG), Sotera Health (SHC), Option Care Health (OPCH), GeneDx (WGS), Privia Health Group (PRVA), Heartflow (HTFL), Veracyte (VCYT), Concentra Group Holdings Parent (CON), and Surgery Partners (SGRY). These companies are all part of the "healthcare" industry. Progyny vs. Its Competitors RadNet BrightSpring Health Services Sotera Health Option Care Health GeneDx Privia Health Group Heartflow Veracyte Concentra Group Holdings Parent Surgery Partners Progyny (NASDAQ:PGNY) and RadNet (NASDAQ:RDNT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations. Do analysts prefer PGNY or RDNT? Progyny currently has a consensus target price of $25.44, suggesting a potential upside of 30.55%. RadNet has a consensus target price of $76.80, suggesting a potential downside of 7.92%. Given Progyny's higher probable upside, analysts plainly believe Progyny is more favorable than RadNet.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Progyny 0 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.70RadNet 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.13 Which has more volatility and risk, PGNY or RDNT? Progyny has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500. Comparatively, RadNet has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Does the media favor PGNY or RDNT? In the previous week, Progyny had 3 more articles in the media than RadNet. MarketBeat recorded 12 mentions for Progyny and 9 mentions for RadNet. RadNet's average media sentiment score of 1.14 beat Progyny's score of 0.45 indicating that RadNet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 4 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral RadNet 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation and earnings, PGNY or RDNT? Progyny has higher earnings, but lower revenue than RadNet. RadNet is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProgyny$1.17B1.44$54.34M$0.5933.03RadNet$1.83B3.51$2.79M-$0.20-417.05 Do insiders & institutionals have more ownership in PGNY or RDNT? 94.9% of Progyny shares are held by institutional investors. Comparatively, 77.9% of RadNet shares are held by institutional investors. 9.4% of Progyny shares are held by company insiders. Comparatively, 5.6% of RadNet shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is PGNY or RDNT more profitable? Progyny has a net margin of 4.28% compared to RadNet's net margin of -0.78%. Progyny's return on equity of 10.69% beat RadNet's return on equity.Company Net Margins Return on Equity Return on Assets Progyny4.28% 10.69% 7.12% RadNet -0.78%2.41%0.82% SummaryProgyny beats RadNet on 11 of the 17 factors compared between the two stocks. Get Progyny News Delivered to You Automatically Sign up to receive the latest news and ratings for PGNY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PGNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PGNY vs. The Competition Export to ExcelMetricProgynyMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.68B$8.46B$6.23B$10.68BDividend YieldN/A2.12%5.71%4.82%P/E Ratio33.0379.4730.0629.84Price / Sales1.4442.77587.23131.17Price / Cash56.5121.6037.0161.44Price / Book3.937.8412.046.60Net Income$54.34M$250.93M$3.32B$276.82M7 Day Performance0.78%3.32%1.79%2.07%1 Month Performance-10.18%-1.10%6.28%2.62%1 Year Performance25.34%17.30%61.13%32.86% Progyny Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PGNYProgyny3.5196 of 5 stars$19.49-0.1%$25.44+30.6%+23.0%$1.68B$1.17B33.03310News CoverageRDNTRadNet3.4539 of 5 stars$71.72+1.6%$76.80+7.1%+22.6%$5.43B$1.83B-358.5811,021Positive NewsBTSGBrightSpring Health Services2.4502 of 5 stars$29.48+3.9%$30.50+3.5%+112.3%$5.02B$11.27B38.3235,000News CoverageEarnings ReportAnalyst ForecastInsider TradeSHCSotera Health2.581 of 5 stars$15.67+2.1%$17.20+9.8%+9.0%$4.36B$1.10B24.363,000Positive NewsOPCHOption Care Health4.6898 of 5 stars$26.67-0.1%$35.11+31.7%-6.7%$4.33B$5.00B18.558,088News CoveragePositive NewsUpcoming EarningsWGSGeneDx2.941 of 5 stars$120.87-0.7%$104.13-13.9%+123.0%$3.50B$305.45M80.081,200Upcoming EarningsAnalyst ForecastPRVAPrivia Health Group2.8852 of 5 stars$24.14+0.2%$28.91+19.8%+47.8%$2.96B$1.74B218.911,140HTFLHeartflowN/A$33.22-0.7%$36.60+10.2%N/A$2.79BN/A0.00699News CoverageVCYTVeracyte3.805 of 5 stars$34.09-2.0%$40.90+20.0%+9.8%$2.74B$445.76M103.31790Analyst ForecastCONConcentra Group Holdings Parent2.5755 of 5 stars$20.17-0.7%$27.75+37.6%-4.1%$2.60B$1.90B16.9511,250News CoverageAnalyst ForecastSGRYSurgery Partners3.783 of 5 stars$19.79+0.3%$32.00+61.7%-30.4%$2.53B$3.11B31.8415,000News CoveragePositive News Related Companies and Tools Related Companies RadNet Alternatives BrightSpring Health Services Alternatives Sotera Health Alternatives Option Care Health Alternatives GeneDx Alternatives Privia Health Group Alternatives Heartflow Alternatives Veracyte Alternatives Concentra Group Holdings Parent Alternatives Surgery Partners Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PGNY) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredTrade this between 9:30 and 10:45 am ESTIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredThe End of Elon Musk…?While headlines point to collapsing sales and fading tax credits, tech analyst Jeff Brown says Tesla is on the...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Progyny, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Progyny With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
